Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Zynlonta, 10mg, powder for concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
loncastuximab tesirine
Company:  
Swedish Orphan Biovitrum Ltd See contact details
ATC code: 
L01FX22
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Zynlonta - Patient Card - NP-45735

{healthcare_pro_orange} For Healthcare Professionals

Risk Management Material in the form of a patient card for Zynlonta. The card will be provided to HCPs to share with patients prescribed Zynlonta

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Swedish Orphan Biovitrum Ltd
Company image
Address
Suite 2, Riverside 3, Granta Park, Great Abington,, Cambridgeshire, CB21 6AD, UK
Telephone
+44 (0) 1223 891854
Medical Information Direct Line
+44 (0) 800 111 4754
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0) 800 111 4754
WWW
http://www.sobi.com